COLL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
COLL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Collegium Pharmaceutical's Enterprise Value is $1,636.4 Mil. Collegium Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $203.3 Mil. Therefore, Collegium Pharmaceutical's EV-to-FCF for today is 8.05.
The historical rank and industry rank for Collegium Pharmaceutical's EV-to-FCF or its related term are showing as below:
During the past 12 years, the highest EV-to-FCF of Collegium Pharmaceutical was 33.27. The lowest was -22.50. And the median was 5.79.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2025-03-20), Collegium Pharmaceutical's stock price is $29.93. Collegium Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $1.860. Therefore, Collegium Pharmaceutical's PE Ratio (TTM) for today is 16.09.
The historical data trend for Collegium Pharmaceutical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
EV-to-FCF | Get a 7-Day Free Trial |
![]() |
![]() |
-2.81 | 6.90 | 10.77 | 4.90 | 7.86 |
Collegium Pharmaceutical Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
EV-to-FCF | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
4.90 | 5.13 | 4.82 | 10.39 | 7.86 |
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's EV-to-FCF falls into.
Collegium Pharmaceutical's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 1636.378 | / | 203.328 | |
= | 8.05 |
Collegium Pharmaceutical's current Enterprise Value is $1,636.4 Mil.
Collegium Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $203.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical (NAS:COLL) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Collegium Pharmaceutical's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 29.93 | / | 1.860 | |
= | 16.09 |
Collegium Pharmaceutical's share price for today is $29.93.
Collegium Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.860.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Collegium Pharmaceutical's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Tupper Colleen | officer: EVP & Chief Financial Officer | C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072 |
Scott Dreyer | officer: EVP & Chief Commercial Officer | 780 DEDHAM STREET, SUITE 800, CANTON MA 02021 |
Shirley R. Kuhlmann | officer: EVP and General Counsel | 780 DEDHAM STREET, SUITE 800, CANTON MA 02021 |
Thomas B Smith | officer: EVP and Chief Medical Officer | BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612 |
Garen G Bohlin | director | C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451 |
Joseph Ciaffoni | director, officer: President and CEO | 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072 |
Michael Thomas Heffernan | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
John Gordon Freund | director | 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301 |
Rita J. Balice-gordon | director | C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072 |
John A. Fallon | director | C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730 |
Gwen A Melincoff | director | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Gino Santini | director | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Neil F. Mcfarlane | director | C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
Richard Malamut | officer: EVP and Chief Medical Officer | 100 TECHNOLOGY CENTER DRIVE, STOUGHTON MA 02072 |
Alison B Fleming | officer: Vice President, Product Devlp | 780 DEDHAM STREET, SUITE 800, CANTON MA 02021 |
From GuruFocus
By Marketwired • 03-17-2025
By GuruFocus News • 02-07-2025
By Marketwired • 02-27-2025
By Marketwired • 11-07-2024
By GuruFocus News • 01-08-2025
By Marketwired • 11-07-2024
By GuruFocus News • 10-11-2024
By Marketwired • 10-24-2024
By GuruFocus News • 11-08-2024
By GuruFocus News • 11-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.